| First Author | Wang L | Year | 2019 |
| Journal | Bone | Volume | 120 |
| Pages | 327-335 | PubMed ID | 30471432 |
| Mgi Jnum | J:270654 | Mgi Id | MGI:6277540 |
| Doi | 10.1016/j.bone.2018.11.014 | Citation | Wang L, et al. (2019) SHP2 regulates intramembranous ossification by modifying the TGFbeta and BMP2 signaling pathway. Bone 120:327-335 |
| abstractText | SHP2 is a ubiquitously expressed protein tyrosine phosphatase, which is involved in many signaling pathways to regulate the skeletal development. In endochondral ossification, SHP2 is known to modify the osteogenic fate of osteochondroprogenitors and to impair the osteoblastic transdifferentiation of hypertrophic chondrocytes. However, how SHP2 regulates osteoblast differentiation in intramembranous ossification remains incompletely understood. To address this question, we generated a mouse model to ablate SHP2 in the Prrx1-expressing mesenchymal progenitors by using "Cre-loxP"-mediated gene excision and examined the development of calvarial bone, in which the main process of bone formation is intramembranous ossification. Phenotypic characterization showed that SHP2 mutants have severe defects in calvarial bone formation. Cell lineage tracing and in situ hybridization data showed less osteoblast differentiation of mesenchymal cells and reduced osteogenic genes expression, respectively. Further mechanistic studies revealed enhanced TGFbeta and suppressed BMP2 signaling in SHP2 ablated mesenchymal progenitors and their derivatives. Our study uncovered the critical role of SHP2 in osteoblast differentiation through intramembranous ossification and might provide a potential target to treat craniofacial skeleton disorders. |
